Objective: To report on the first successful pregnancy performing preimplantation genetic diagnosis (PGD) on embryos obtained after combining natural IVF with in vitro maturation procedure. Design: Case report. Settin...Objective: To report on the first successful pregnancy performing preimplantation genetic diagnosis (PGD) on embryos obtained after combining natural IVF with in vitro maturation procedure. Design: Case report. Setting: University hospital. Patient(s): A 35- year-old patient with polycystic ovaries who was attending the fertility clinic. Intervention(s): In vitro maturation of immature oocytes and preimplantation genetic diagnosis. Main Outcome Measure(s): Preimplantation genetic diagnosis of aneuploidy screening in embryos produced from in vitro maturation procedure. Result(s): Thirteen immature and two mature oocytes were collected, and eight mature oocytes were normally fertilized, of which six embryos were biopsied for chromosome analysis. Two chromosomally normal embryos were transferred on day 5, resulting in the birth of a healthy child. Conclusion(s): This case report demonstrates that an acceptable number of embryos can be generated after in vitro maturation procedure to perform PGD for aneuploidy screening and that this approach can be extended to patients with polycystic ovaries or polycystic ovary syndrome who are undergoing PGD for other genetic diseases.展开更多
To evaluate the pharmacokinetic, pharmacodynamic, and safety profiles of the a romatase inhibitor anastrozole in healthy, premenopausal women. Phase I, single -center study. Infertility clinic. Twenty-six women with r...To evaluate the pharmacokinetic, pharmacodynamic, and safety profiles of the a romatase inhibitor anastrozole in healthy, premenopausal women. Phase I, single -center study. Infertility clinic. Twenty-six women with regular ovulatory cyc les: 20 received either a single dose of 5 mg, 10 mg, 15 mg, or 20 mg anastrozol e, or remained untreated; 6 received five daily doses of 10 mg or 15 mg anastroz ole. Anastrozole was administered on cycle day 2 for the single-dose groups and on days 26 for the multiple-dose groups. Ultrasound follicular development and endometrial biopsies were performed. Safety was determined from adverse event r eports and laboratory parameters. Pharmacokinetics, pharmacodynamics, and safety . The pharmacokinetics of anastrozole were linear, predictable, and consistent w ith previously published data in healthy volunteers. In the single-dose groups, E2 levels reached their nadir 36 hours after administration, decreasing by an a verage of 39%from baseline. Follicle-stimulating hormone levels rose by 13%, 52%, 49%, and 75%in the 5-mg, 10-mg, 15-mg, and 20-mg groups, respectivel y, at approximately 24 hours after dosing. Most subjects recruited just one matu re follicle, with no apparent effect on endometrial maturation. No safety concer ns were noted. Anastrozole was well tolerated and suppressed E2 levels, with a r esultant increase in FSH.展开更多
Objective: To elucidate the possible mechanisms of immunotherapy for unexplained recurrent aborters using their husband’s mononuclear cells. Design: Prospective clinical study. Setting: Institutional practice at the ...Objective: To elucidate the possible mechanisms of immunotherapy for unexplained recurrent aborters using their husband’s mononuclear cells. Design: Prospective clinical study. Setting: Institutional practice at the Outpatient Clinic for Infertility, Niigata University Medical Hospital. Patient(s): Fifty-two unexplained recurrent aborters were chosen as an experimental group. Intervention(s): Each patient was injected with her husband’s mononuclear cells as immunotherapy. Peripheral blood was obtained from the patients. Main Outcome Measure(s): The percentage of CD4-positive cells, TH1 cells, TH2 cells, and the TH1/TH2 ratio were analyzed in the patients before and after immunotherapy. The same analyses were performed in the successful and the unsuccessful group. Result(s): To date, 42 of the 52 patients have become newly pregnant. Of the 42, 34 patients have already delivered (successful group) and 3 are now pregnant, while the remaining 8 cases experienced repeated abortion (unsuccessful group). The percentage of TH2 cells significantly increased in the total patient population, while the TH1/TH2 ratio significantly decreased in the total patient population and in the successful group. Conclusion(s): These findings suggest that immunotherapy with the husband’s mononuclear cells for unexplained recurrent abortion induces a dominant state of TH2 cells in the patients.展开更多
文摘Objective: To report on the first successful pregnancy performing preimplantation genetic diagnosis (PGD) on embryos obtained after combining natural IVF with in vitro maturation procedure. Design: Case report. Setting: University hospital. Patient(s): A 35- year-old patient with polycystic ovaries who was attending the fertility clinic. Intervention(s): In vitro maturation of immature oocytes and preimplantation genetic diagnosis. Main Outcome Measure(s): Preimplantation genetic diagnosis of aneuploidy screening in embryos produced from in vitro maturation procedure. Result(s): Thirteen immature and two mature oocytes were collected, and eight mature oocytes were normally fertilized, of which six embryos were biopsied for chromosome analysis. Two chromosomally normal embryos were transferred on day 5, resulting in the birth of a healthy child. Conclusion(s): This case report demonstrates that an acceptable number of embryos can be generated after in vitro maturation procedure to perform PGD for aneuploidy screening and that this approach can be extended to patients with polycystic ovaries or polycystic ovary syndrome who are undergoing PGD for other genetic diseases.
文摘To evaluate the pharmacokinetic, pharmacodynamic, and safety profiles of the a romatase inhibitor anastrozole in healthy, premenopausal women. Phase I, single -center study. Infertility clinic. Twenty-six women with regular ovulatory cyc les: 20 received either a single dose of 5 mg, 10 mg, 15 mg, or 20 mg anastrozol e, or remained untreated; 6 received five daily doses of 10 mg or 15 mg anastroz ole. Anastrozole was administered on cycle day 2 for the single-dose groups and on days 26 for the multiple-dose groups. Ultrasound follicular development and endometrial biopsies were performed. Safety was determined from adverse event r eports and laboratory parameters. Pharmacokinetics, pharmacodynamics, and safety . The pharmacokinetics of anastrozole were linear, predictable, and consistent w ith previously published data in healthy volunteers. In the single-dose groups, E2 levels reached their nadir 36 hours after administration, decreasing by an a verage of 39%from baseline. Follicle-stimulating hormone levels rose by 13%, 52%, 49%, and 75%in the 5-mg, 10-mg, 15-mg, and 20-mg groups, respectivel y, at approximately 24 hours after dosing. Most subjects recruited just one matu re follicle, with no apparent effect on endometrial maturation. No safety concer ns were noted. Anastrozole was well tolerated and suppressed E2 levels, with a r esultant increase in FSH.
文摘Objective: To elucidate the possible mechanisms of immunotherapy for unexplained recurrent aborters using their husband’s mononuclear cells. Design: Prospective clinical study. Setting: Institutional practice at the Outpatient Clinic for Infertility, Niigata University Medical Hospital. Patient(s): Fifty-two unexplained recurrent aborters were chosen as an experimental group. Intervention(s): Each patient was injected with her husband’s mononuclear cells as immunotherapy. Peripheral blood was obtained from the patients. Main Outcome Measure(s): The percentage of CD4-positive cells, TH1 cells, TH2 cells, and the TH1/TH2 ratio were analyzed in the patients before and after immunotherapy. The same analyses were performed in the successful and the unsuccessful group. Result(s): To date, 42 of the 52 patients have become newly pregnant. Of the 42, 34 patients have already delivered (successful group) and 3 are now pregnant, while the remaining 8 cases experienced repeated abortion (unsuccessful group). The percentage of TH2 cells significantly increased in the total patient population, while the TH1/TH2 ratio significantly decreased in the total patient population and in the successful group. Conclusion(s): These findings suggest that immunotherapy with the husband’s mononuclear cells for unexplained recurrent abortion induces a dominant state of TH2 cells in the patients.
